Clinical Trials Browser

Breast Diseases, Breast Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT01199068 2021-05-13

CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)

Phase 1 Completed

15 enrolled 14 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Respiratory Tract Neoplasms

NCT01636908 2021-04-15

ICK

Phase NA Completed

43 enrolled

Tumor-Agnostic

Neoplasms

NCT00848718 2019-11-12

MK-2206-003

Phase 1 Completed

77 enrolled 24 charts

Tumor-Agnostic

Neoplasms

NCT01545947 2019-11-12

Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer

Phase 1 Completed

76 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT00497224 2019-05-30

Phase II Trial of Erlotinib in Advanced Pancreatic Cancer

Phase 2 Completed

51 enrolled

Gastrointestinal

Adenocarcinoma, Neoplasms, Pancreatic Neoplasms

NCT02889692 2019-04-11

Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma

Phase 3 Completed

23 enrolled

Thoracic

Lung Neoplasms, Neoplasms

NCT01472016 2017-11-21

Study of ABT-700 in Subjects With Advanced Solid Tumors

Phase 1 Completed

74 enrolled

Tumor-Agnostic

Neoplasms

NCT01192165 2017-11-13

Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel

Phase 1 Completed

169 enrolled

Tumor-Agnostic

Neoplasms

NCT00369512 2017-05-30

RAD0503

Phase 2 Completed

15 enrolled 9 charts

Tumor-Agnostic

Carcinoma, Squamous Cell, Neoplasms

NCT01482377 2017-01-27

A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin

Phase 1 Completed

145 enrolled

Tumor-Agnostic

Neoplasms

NCT00705874 2016-07-21

Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma

Phase 1 Completed

172 enrolled 13 charts

Lymphoid

Lymphoma, Neoplasms

NCT00207077 2015-10-28

Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors

Phase 1 Completed

33 enrolled

Tumor-Agnostic

Neoplasms

NCT00585377 2015-09-24

Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer

Phase 2 Completed

50 enrolled 7 charts

Tumor-Agnostic

Neoplasms

NCT00109265 2015-07-02

A Study to Evaluate Erlotinib in Patients With Advanced or Metastatic Breast Cancer During or Following Chemotherapy

Phase 2 Completed

Breast

Breast Neoplasms, Neoplasms

NCT01727869 2015-04-06

Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer

Phase 1 Completed

56 enrolled

Tumor-Agnostic

Neoplasms

NCT01565538 2014-09-15

Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma

Phase 2 Completed

123 enrolled 9 charts

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT00884845 2014-03-26

Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors

Phase 1 Completed

35 enrolled

Tumor-Agnostic

Neoplasms

NCT00725634 2014-01-27

P05538

Phase 1 Completed

41 enrolled

LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Neoplasms, Plasma Cell

NCT00418704 2013-10-01